We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Higher inflation and unfavorable mix more than offset Clorox's cost-saving benefits in the quarter.
Clorox expects the FY27 gross margin of 42% as inflation and negative mix remain the key headwinds.
The Clorox Company (CLX - Free Report) is leaning on productivity initiatives and cost savings to counter persistent inflationary pressure, but near-term margin protection remains challenging. In the fourth quarter of fiscal 2026, the gross margin contracted 520 basis points year over year to 41.3%. Management attributed the decline mainly to higher-than-normal inflation and unfavorable mix, which more than offset benefits from cost-saving initiatives. The comparison also included about 150 basis points of pressure from lower operating leverage related to the ERP transition and another 150 basis points from GOJO acquisition-related inventory step-up.
Clorox continues to strengthen its cost structure. In fiscal 2026, the company expanded its cost-saving programs and established infrastructure designed to improve operational efficiency and generate funds for reinvestment. With the ERP implementation now completed, management is shifting from stabilization to optimization, with a focus on capturing productivity benefits, removing costs and realizing the system’s full potential.
Still, inflation is likely to remain a significant headwind in fiscal 2027. Clorox expects volatility in energy and commodity markets, elevated logistics expenses, and supply-chain pressures to keep input-cost inflation sticky. The company projects fiscal 2027 gross margin of 42%, with stronger-than-normal inflation and negative mix expected to more than offset holistic margin-management benefits.
Thus, cost savings should provide an important cushion, but they may not fully offset inflation in the near term. Longer term, productivity gains, pricing actions and disciplined margin management could support a gradual margin recovery.
Zacks Rundown for Clorox
CLX shares have risen 5.2% in the past three months compared with the industry and the Consumer Staples sector’s growth of 7.1% and 5.8%, respectively. The Zacks Rank #5 (Strong Sell) company has outpaced the S&P 500’s decline of 0.3% in the same period.
Clorox’s 3-Month Price Performance
Image Source: Zacks Investment Research
From a valuation standpoint, CLX is trading at a forward price-to-earnings ratio of 15.97X, lower than the industry’s 18.74X multiple.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Clorox’s fiscal 2027 and 2028 earnings implies year-over-year growth of 6% and 8.9%, respectively. Earnings estimates for fiscal 2027 and 2028 have moved down 2.8% and 1.7% in the past 30 days.
Image Source: Zacks Investment Research
Three Stocks Looking Good
The Vita Coco Company Inc. (COCO - Free Report) is the leading coconut water brand in the United States, leveraging its strong brand equity, expanding global presence and asset-light business model to capitalize on the growing demand for healthier hydration beverages. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Vita Coco’s current financial-year sales and earnings indicates growth of 31.6% and 64.7%, respectively, from the prior-year reported levels. COCO delivered a trailing four-quarter earnings surprise of 21.9%, on average.
National Vision Holdings, Inc. (EYE - Free Report) is a value-focused optical retailer in the United States. The company currently carries a Zacks Rank of 2 (Buy).
The Zacks Consensus Estimate for National Vision’s current financial-year sales and earnings is expected to rise 3.8% and 22.5%, respectively, from the year-ago reported figures. EYE delivered a trailing four-quarter earnings surprise of 52.5%, on average.
Purple Innovation Inc. (PRPL - Free Report) designs and manufactures products which include mattresses, pillows and cushions, using its patented Hyper-Elastic Polymer. The company currently carries a Zacks Rank of 2.
The Zacks Consensus Estimate for Purple Innovation’s current financial-year sales and earnings indicates growth of 0.4% and 20.8%, respectively, from the year-ago reported numbers. PRPL delivered a trailing four-quarter earnings surprise of 21.3%, on average.
View the Zacks #1 Rank List
Image: Bigstock
Can Cost Savings Offset Inflation & Protect Clorox's Margins?
Key Takeaways
The Clorox Company (CLX - Free Report) is leaning on productivity initiatives and cost savings to counter persistent inflationary pressure, but near-term margin protection remains challenging. In the fourth quarter of fiscal 2026, the gross margin contracted 520 basis points year over year to 41.3%. Management attributed the decline mainly to higher-than-normal inflation and unfavorable mix, which more than offset benefits from cost-saving initiatives. The comparison also included about 150 basis points of pressure from lower operating leverage related to the ERP transition and another 150 basis points from GOJO acquisition-related inventory step-up.
Clorox continues to strengthen its cost structure. In fiscal 2026, the company expanded its cost-saving programs and established infrastructure designed to improve operational efficiency and generate funds for reinvestment. With the ERP implementation now completed, management is shifting from stabilization to optimization, with a focus on capturing productivity benefits, removing costs and realizing the system’s full potential.
Still, inflation is likely to remain a significant headwind in fiscal 2027. Clorox expects volatility in energy and commodity markets, elevated logistics expenses, and supply-chain pressures to keep input-cost inflation sticky. The company projects fiscal 2027 gross margin of 42%, with stronger-than-normal inflation and negative mix expected to more than offset holistic margin-management benefits.
Thus, cost savings should provide an important cushion, but they may not fully offset inflation in the near term. Longer term, productivity gains, pricing actions and disciplined margin management could support a gradual margin recovery.
Zacks Rundown for Clorox
CLX shares have risen 5.2% in the past three months compared with the industry and the Consumer Staples sector’s growth of 7.1% and 5.8%, respectively. The Zacks Rank #5 (Strong Sell) company has outpaced the S&P 500’s decline of 0.3% in the same period.
Clorox’s 3-Month Price Performance
Image Source: Zacks Investment Research
From a valuation standpoint, CLX is trading at a forward price-to-earnings ratio of 15.97X, lower than the industry’s 18.74X multiple.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Clorox’s fiscal 2027 and 2028 earnings implies year-over-year growth of 6% and 8.9%, respectively. Earnings estimates for fiscal 2027 and 2028 have moved down 2.8% and 1.7% in the past 30 days.
Image Source: Zacks Investment Research
Three Stocks Looking Good
The Vita Coco Company Inc. (COCO - Free Report) is the leading coconut water brand in the United States, leveraging its strong brand equity, expanding global presence and asset-light business model to capitalize on the growing demand for healthier hydration beverages. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Vita Coco’s current financial-year sales and earnings indicates growth of 31.6% and 64.7%, respectively, from the prior-year reported levels. COCO delivered a trailing four-quarter earnings surprise of 21.9%, on average.
National Vision Holdings, Inc. (EYE - Free Report) is a value-focused optical retailer in the United States. The company currently carries a Zacks Rank of 2 (Buy).
The Zacks Consensus Estimate for National Vision’s current financial-year sales and earnings is expected to rise 3.8% and 22.5%, respectively, from the year-ago reported figures. EYE delivered a trailing four-quarter earnings surprise of 52.5%, on average.
Purple Innovation Inc. (PRPL - Free Report) designs and manufactures products which include mattresses, pillows and cushions, using its patented Hyper-Elastic Polymer. The company currently carries a Zacks Rank of 2.
The Zacks Consensus Estimate for Purple Innovation’s current financial-year sales and earnings indicates growth of 0.4% and 20.8%, respectively, from the year-ago reported numbers. PRPL delivered a trailing four-quarter earnings surprise of 21.3%, on average.